Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 286

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 286
---
 by the Required Holders (as defined in the Series B Certificate of Designations) under the Series B Certificate of Designations. As of the date of this prospectus, all of the authorized shares of Series B Preferred Stock, which we previously issued, have been converted into shares of Common Stock and there are no longer any shares of Series B Preferred Stock outstanding. Series C Convertible Preferred Stock We designated 2,853 shares of our authorized and unissued Preferred Stock as Series C Preferred Stock and established the rights, preferences and privileges of the Series C Preferred Stock pursuant to the Series C Certificate of Designations filed with the Secretary of State of the State of Delaware, as summarized below. Except as set forth below, the Series C Preferred Stock has terms and provisions that are substantially the same as those of the Series A Preferred Stock and Series B Preferred Stock. 169 Ranking.The Series C Preferred Stock, with respect to the payment of dividends, distributions and payments upon the liquidation, dissolution and winding up of us, ranks senior to all of our capital stock (including the Series A Preferred Stock and the Series B Preferred Stock) unless the Required Holders (as defined in the Series C Certificate of Designations) consent to the creation of other capital stock that is senior or equal in rank to the Series C Preferred Stock. As described below, the Required Holders of the Series C Preferred Stock consented to the issuance of the Series D Preferred Stock and Series E Preferred Stock, ranking pari passu therewith. Conversion Rights Conversion at Option of Holder.Each holder of Series C Preferred Stock may convert all, or any part, of the outstanding Series C Preferred Stock, at any time at such holder’s option, into shares of the Common Stock (which converted shares of Common Stock are referred to as “Series C Conversion Shares” herein) at a current “Series C Conversion Price” of $0.05 (following certain adjustments since the original issuance of such shares of Series C Preferred Stock), which is subject to proportional adjustment upon the occurrence of any stock split, stock dividend, stock combination and/or similar transactions. Alternate Conversion Upon a Triggering Event.Following the occurrence and during the continuance of a Series C Triggering Event (as defined below), each holder may alternatively elect to convert the Series C Preferred Stock at the “Series C Alternate Conversion Price” equal to the lesser of:

| ● | the Conversion Price, and |

| ● | the greater of: |

| ● | the floor price of $39.20 (originally $0